Efficacy
After a median follow up of 3.6 years, the DFS rate was 74.1% in the capecitabine group vs 67.6% in the control group (HR=0.70; 95% CI, 0.53 to 0.92, p=0.01). Among the triple negative breast cancer (TNBC) patients, the DFS rate was 69.8% vs 56.1% respectively (HR=0.58; 95% CI, 0.39 to 0.87).r
Kaplan-Meier curve of DFS in (A) HER2-negative patients and (C) TNBC patientsr
© N Engl J Med 2017
The OS rate was 89.2% in the capecitabine group vs 83.6% in the control group (HR=0.59; 95% CI, 0.39 to 0.90, p=0.01). In the TNBC group, the OS rate was 78.8% vs 70.3% respectively (HR=0.52; 95% CI, 0.30 to 0.90).
Kaplan-Meier curve of OS in (B) HER2-negative patients and (D) TNBC patientsr
© N Engl J Med 2017